An in vitro study of epoetin beta intravenous injection site at the end of hemodialysis.
The aim of this study (SITEPO) is to evaluate the influence of the intravenous injection site (drip chamber injection site, venous injection site or venous fistula needle) on plasma concentration of epoetin beta (Neorecormon, Roche), a recombinant Human Erythropoietin (rHuEPO), at the end of in vitro hemodialysis sessions. No practical administration guidelines are available. Twenty 1-h dialysis sessions are performed. Before each dialysis, the circuit is filled with 270ml, of heparinized total human blood whose hematocrit is adjusted to 35%. A common dosage of epoetin beta in clinical practice (3000IU) is studied for the three injection sites and for reference experiments in which rHuEPO is not injected into the dialysis circuit. Plasma concentrations of erythropoietin are measured by ELISA. The physiologically endogenous erythropoietin concentration is systematically determined and removed from the total epoetin beta concentration. Average epoetin beta plasma levels returned are not significantly different between the three injection sites and no significant rHuEPO loss is observed after injection into the drip chamber, the venous injection site and the venous fistula needle compared with reference experiments. The three intravenous injection sites of rHuEPO can be used at the end of dialysis without significant epoetin beta loss.
Xuereb
Fabien
F
EA 2968 Laboratoire de Pharmacocinétique et de Pharmacie Clinique, Université Victor Segalen Bordeaux 2, 146 Rue Léo-Saignat, 33076 Bordeaux, Cedex, France. fabien.xuereb@chu-bordeaux.fr
de Précigout
Valérie
V
Combe
Christian
C
Sinnasse-Raymond
Gilles
G
Saux
Marie-Claude
MC
Breilh
Dominique
D
D001166:Arteriovenous Shunt, Surgical; D002405:Catheterization, Central Venous / Q000295:instrumentation; D002408:Catheters, Indwelling; D004797:Enzyme-Linked Immunosorbent Assay; D004867:Equipment Design; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood; D006397:Hematinics / Q000008:administration & dosage* / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D011677:Punctures; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin